Last reviewed · How we verify
Hydralazine and magnesium valproate
This combination uses hydralazine as a vasodilator and magnesium valproate as a histone deacetylase inhibitor to modulate vascular function and epigenetic pathways in cancer treatment.
This combination uses hydralazine as a vasodilator and magnesium valproate as a histone deacetylase inhibitor to modulate vascular function and epigenetic pathways in cancer treatment. Used for Cancer (specific indication not publicly detailed; Phase 3 trial status suggests solid tumor or hematologic malignancy under investigation).
At a glance
| Generic name | Hydralazine and magnesium valproate |
|---|---|
| Also known as | TRANSKRIP R/L |
| Sponsor | National Institute of Cancerología |
| Drug class | Combination therapy: vasodilator + histone deacetylase inhibitor |
| Target | HDAC (histone deacetylase); vascular smooth muscle relaxation pathways |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Hydralazine is a direct-acting vasodilator that relaxes vascular smooth muscle and may have immunomodulatory effects. Magnesium valproate (valproic acid) is a histone deacetylase (HDAC) inhibitor that promotes histone acetylation, leading to altered gene expression and potential anti-tumor effects. The combination may work synergistically to inhibit angiogenesis and promote differentiation or apoptosis in cancer cells.
Approved indications
- Cancer (specific indication not publicly detailed; Phase 3 trial status suggests solid tumor or hematologic malignancy under investigation)
Common side effects
- Headache
- Dizziness
- Nausea
- Thrombocytopenia
- Hepatotoxicity
Key clinical trials
- Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer (PHASE3)
- Hydralazine Valproate for Cervical Cancer (PHASE3)
- Hydralazine Valproate for Ovarian Cancer (PHASE3)
- A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors (PHASE2)
- Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer (PHASE2)
- Hydralazine and Valproate Added to Chemotherapy for Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: